Dashboard
1
The company is Net-Debt Free
- Poor long term growth as Net Sales has grown by an annual rate of 6.00% and Operating profit at 0.20% over the last 5 years
- The company is Net-Debt Free
2
Poor long term growth as Net Sales has grown by an annual rate of 6.00% and Operating profit at 0.20% over the last 5 years
3
Negative results in Jun 26
4
With ROE of 11.22%, it has a very expensive valuation with a 6.62 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
JPY 510,998 Million (Mid Cap)
59.00
NA
0.00%
0.38
11.22%
5.84
Revenue and Profits:
Net Sales:
21,632 Million
(Quarterly Results - Jun 2026)
Net Profit:
1,299 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-40.02%
0%
-40.02%
6 Months
-24.15%
0%
-24.15%
1 Year
78.4%
0%
78.4%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Rigaku Holdings Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
6.00%
EBIT Growth (5y)
0.20%
EBIT to Interest (avg)
19.38
Debt to EBITDA (avg)
1.01
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
8,145.19
Tax Ratio
28.02%
Dividend Payout Ratio
37.46%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
504,342.99%
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
59
Industry P/E
Price to Book Value
6.62
EV to EBIT
40.30
EV to EBITDA
29.83
EV to Capital Employed
5.06
EV to Sales
6.69
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
12.55%
ROE (Latest)
11.22%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
21,632.00
17,933.00
20.63%
Operating Profit (PBDIT) excl Other Income
3,289.00
2,240.00
46.83%
Interest
389.00
301.00
29.24%
Exceptional Items
0.00
0.00
Consolidate Net Profit
1,299.00
329.00
294.83%
Operating Profit Margin (Excl OI)
86.90%
46.70%
4.02%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 20.63% vs -48.32% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is 294.83% vs -95.38% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
94,193.00
90,652.00
3.91%
Operating Profit (PBDIT) excl Other Income
22,436.00
23,359.00
-3.95%
Interest
1,143.00
755.00
51.39%
Exceptional Items
-23.00
-106.00
78.30%
Consolidate Net Profit
11,401.00
13,615.00
-16.26%
Operating Profit Margin (Excl OI)
184.10%
204.00%
-1.99%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 3.91% vs 13.48% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -16.26% vs 24.86% in Dec 2024
Footer loading






